Galedra

Claims

Search Type State Status Topic Model Order Counting Over

As of snapshot 27745 under ledger-default@0.3.0.

Claim	Type	Assessment	Score	Review checks	References
In the 2026 HERBOT phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen had a 95% disease-control rate.	QUANTITATIVE	Supported	0.8808	1 of 4	84